Naoya Akazawa

Sendai, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

Journal: JAMA oncology
Published: July 03, 2026

Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery A Prospective Cohort Study: Erratum.

Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery A Prospective Cohort Study: Erratum.

Journal: Annals of surgery
Published: April 09, 2026

Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer.

Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer.

Journal: International journal of clinical oncology
Published: April 08, 2026

Two Cases of Appendiceal Goblet Cell Adenocarcinoma Diagnosed after Appendectomy

Two Cases of Appendiceal Goblet Cell Adenocarcinoma Diagnosed after Appendectomy

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026

Corrigendum to "A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)": [ESMO Open. Volume 10, Issue 9, (September 2025) 105571].

Corrigendum to "A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)": [ESMO Open. Volume 10, Issue 9, (September 2025) 105571].

Journal: ESMO open
Published: January 03, 2026

Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial.

Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial.

Journal: Targeted oncology
Published: November 20, 2025

Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection.

Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection.

Journal: NPJ precision oncology
Published: October 22, 2025

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Journal: European journal of cancer (Oxford, England : 1990)
Published: October 14, 2025

Evaluation of a novel standardized education program for centrally inserted central catheters insertion in a region of Japan.

Evaluation of a novel standardized education program for centrally inserted central catheters insertion in a region of Japan.

Journal: The journal of vascular access
Published: September 19, 2025

Catheter tip migration following power injection of contrast medium through a pressure-resistant central venous port: A case report.

Catheter tip migration following power injection of contrast medium through a pressure-resistant central venous port: A case report.

Journal: Radiology case reports
Published: June 20, 2025

A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study).

A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study).

Journal: ESMO open
Published: June 07, 2025

Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study.

Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study.

Journal: Annals of surgery
Published: May 29, 2025
Showing 1-12 of 43

Last Updated: 09/26/2026